Quantcast
Last updated on April 23, 2014 at 20:10 EDT

Latest Somatostatin Stories

2013-09-18 12:31:10

GARCHING, Germany, September 18, 2013 /PRNewswire/ -- - In-licensing of superior DOTA-Tyr3-octreotide - Pharmaceutical developmentfor treatment of NETs - Excellent pharmacokinetic properties ITM Isotope Technologies Munich AG (ITM) today announced that it has entered into an exclusive licensing agreement with Progenics Pharmaceuticals Inc. for pharmaceutical development and commercialization of radiolabeled DOTA-conjugated somatostatin...

2013-09-10 04:22:07

LUND, Sweden, September 10, 2013 /PRNewswire/ -- Camurus announced today that Novartis has exercised its option to acquire an exclusive license for the further development and worldwide commercialization of CAM2029 for treatment of patients with acromegaly and neuroendocrine tumors (NETs). The license also covers additional future products based on the Camurus' FluidCrystal(R) Injection depot technology. (Logo:...

2013-02-18 08:23:10

BASEL, Switzerland, NEW YORK and JERUSALEM, Feb. 18, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-az-ma) Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreolin is an investigational oral form of the peptide octreotide, a somatostatin analog that is...

2012-10-12 07:23:03

THE WOODLANDS, Texas, Oct. 12, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a registrational, Phase 3 clinical trial of telotristat etiprate, an investigational new drug candidate for the treatment of carcinoid syndrome. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the...

2012-10-12 07:22:58

THE WOODLANDS, Texas, Oct. 12, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line data from a recently completed Phase 2 study in carcinoid syndrome with telotristat etiprate. Results from the trial will be presented at the North American Neuroendocrine Tumor Society on Saturday, October 13, 2012 in San Diego, California. Carcinoid syndrome is a chronic...

2012-07-09 11:24:01

Selectively modifying hormones and using them as medicinal substances Researchers at the RUB and from Berkeley have used metal complexes to modify peptide hormones. In the Journal of the American Chemical Society, they report for the first time on the three-dimensional structure of the resulting metal-peptide compounds. "With this work, we have laid the molecular foundation for the development of better medicines" says Prof. Raphael Stoll from the Faculty of Chemistry and Biochemistry at...

Obesity Vaccine Keeps People Trim
2012-07-09 11:17:44

Lawrence LeBlond for redOrbit.com - Your Universe Online The global obesity epidemic has continued to burgeon without any solid intervention to halt and reverse an issue that now affects more than 1 in 3 people. Yet, that could change with the development of a new vaccine that scientists are hoping will keep the pounds off at the dinner table. The vaccine -- dubbed the “flab jab” -- is the invention of scientists at the South Dakota, US company Braasch Biotech with Dr. Keith...

2012-06-26 10:24:10

Chiasma Developing Oral Alternative to Injectable Somatostatin Analogs; Phase 3 Trial Under Way HOUSTON, June 26, 2012 /PRNewswire-USNewswire/ -- Chiasma, a privately held biopharma company, today presented data at the annual meeting of The Endocrine Society (ENDO 2012) that show Octreolin, an investigational new oral drug being developed for use in acromegaly, reduced pituitary growth hormone secretion in healthy volunteers as effectively as shown in published studies of injectable...

2011-11-30 10:45:17

Combination treatment with octreotide shows improved results in tumors associated with carcinoid syndrome Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, according to researchers at The University of Texas MD Anderson Cancer Center. Results of the international, randomized, placebo-controlled...

2011-08-06 00:00:29

Cabergolean is the most powerful HGH Booster, Prolactin Inhibitor, and Nutraceutical Nootropic ever to be sold as a nutritional supplement. Cabergolean also acts as a powerful Nitric Oxide (NO) Releaser, and Sleep Enhancer. Cabergolean naturally increases endogenous production of HGH through a clinically proven increase in GHRH (Growth Hormone Releasing Hormone) and through the suppression of GHIH (Growth Hormone Inhibiting Hormone or Somatostatin). Chicago, IL (PRWEB) August 05, 2011...